Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Kristina S BoyeMatthew C RiddleUlagamadesan VenkatesanReema ModyLuis-Emilio Garcia-PerezChrisanthi A KaranikasMaureen J LageJeffrey S RiesmeyerMark C LakshmananPublished in: Diabetes, obesity & metabolism (2019)
Although none of the trials are fully representative of the general population, among the four trials examined, results from baseline REWIND were found to be more generalizable to the US adult T2D population than those of other GLP-1 RA CVOTs.